U.S. News: New form of levodopa might improve Parkinson's care
UC researcher presents trial results at national conference
Several national outlets, including U.S. News & World Report, highlighted new research from the University of Cincinnati's Alberto Espay.
Espay, MD, presented research at the American Academy of Neurology annual meeting that found an extended-release formulation of a Parkinson's drug could lead to more time where patients' symptoms are well managed.
Three doses of the new drug, called IPX203, was found to work slightly better at providing better "on time," or time where the medication is working and symptoms are lessened, compared to five doses of the standard formulation.
"If our brains aren’t making enough levodopa, then we have less of the dopamine that we need for movement and emotional regulation,” Espay told U.S. News. “Levodopa is to Parkinson’s what insulin is to diabetes. It’s actually replenishing something that the brain makes, but in these patients is making a little less than they need.
“This might well be used with five doses a day, and then this will be a marked improvement,” Espay continued. “Most patients really don't mind. What they're worried about is not how frequently they are taking it, but how much ‘off time’ they still may have. They don't want to have ‘off time’ regardless of how many times it takes for them to dose themselves.”
Read the U.S. News & World Report story, originally published on HealthDay.
Read additional coverage of the research on Neurology Live and MedicalResearch.com.
Espay also presented research on a subcutaneous delivery system for levodopa-carbidopa to treat Parkinson's at the conference.
Read the MedPage Today article on the research.
Read Neurology Live coverage of the research.
Featured photo at top of 3-D illustration of a dopamine molecule. Photo/Dr_Microbe/iStock.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
Is going nuclear the solution to Ohio’s energy costs?
November 10, 2025
The Ohio Capital Journal recently reported that as energy prices continue to climb, economists are weighing the benefits of going nuclear to curb costs. The publication dove into a Scioto Analysis survey of 18 economists to weigh the pros and cons of nuclear energy. One economist featured was Iryna Topolyan, PhD, professor of economics at the Carl H. Lindner College of Business.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.